
## RECEIVED 2005 APR 25 P 4: 12



### CARL ZEISS MEDITEC



### Carl Zelss Meditec AG 07740 Jena

Securities and Exchange Commission Division of Corporation Finance Office of International Corporate Finance 450 Fifth Street, N. W.

Washington, D. C. 20549 United States

Division/ Dept.:

**Investor Relations** 

Your contact: Jens Brajer

File No. 82-34817



SUPPL

Carl Zeiss Meditec AG Goeschwitzer Strasse 51-52 07745 Jena Germany

Tel: +49 (0) 36 41/220-105

Fax: +49 (0) 36 41/220-117

e-mail: j.brajer@meditec.zeiss.com

Our ref.: JB/Mtr

2005-04-15

Dear Ladies and Gentlemen,

Please find attached the following document that was released to our shareholders:

Type of document	Date of release
Press release	2005-04-15

Best regards,

Carl Zeiss Meditec AG

Jens Brajer

**Director Investor Relations** 

i. A.

Mandy Treffer

**Assistant Investor Relations** 

PROCESSED

**Board of Management:** Ulrich Krauss (CEO) **Bernd Hirsch** Chairman of the Supervisory Board: Dr. Michael Kaschke

Deutsche Bank AG Jena Account: 62 453 69 (BLZ: 820 700 00) SWIFT: DEUT DE 8E IBAN: DE90820700000624536900 Commercial register: Gera, HRB 5623 VAT-IdNo. DE 811 922 737 Tax-No. 64003/02707

Commerzbank Jena

Account: 258072800 (BLZ: 820 40000)

SWIFT: COBADEFFXXX

IBAN: DE31820400000258072800 Phone: +49 (0) 36 41/220-0

Fax: +49 (0) 36 41/ 220-112 Internet: www.meditec.zeiss.com e-mail: info@meditec.zeiss.com



# Carl Zeiss Meditec - Majority shareholding IOLTECH with good revenues development in past financial year

Jena, 15 April 2005 – The French ophthalmic surgery specialist IOLTECH S.A., in which Carl Zeiss Meditec AG (ISIN: DE0005313704) holds a controlling majority of 87 percent, today published its sales revenues for the financial year 2004/2005 (end: February 28, 2005) in accordance with statutory provisions in France. Accordingly, during this period IOLTECH posted a turnover of € 54.1 million (previous year: € 44.7 m). This corresponds to an increase of 21% over the previous year. More than half of the IOLTECH revenues were generated outside its native market, France. Given the fact that integration of IOLTECH and Carl Zeiss Meditec has already commenced, both companies consider this result to be a major success.

As of 1 February 2005, Carl Zeiss Meditec, medical technology supplier listed in the Prime Standard at the Deutsche Börse, had acquired in a first step about 63 percent of the IOLTECH shares from its former majority shareholder Philippe Tourrette. Accordingly, from this date onwards the activities of IOLTECH are reflected in the consolidated financial statements of Carl Zeiss Meditec. In a second step about two thirds of the remaining IOLTECH shareholders agreed to the takeover by Carl Zeiss Meditec by accepting the corresponding takeover bid. Thus, Carl Zeiss Meditec now holds 87.1% of the shares in IOLTECH. Until the takeover of IOLTECH S.A. will have been completed by Carl Zeiss Meditec, the company remains listed on the French stock exchange Euronext.

In accordance with the statutory provisions in France IOLTECH S.A. will submit its full figures for the financial year 2004/2005 in May 2005.

15 April 2005 Page 2 of 2



### **Brief Profile**

Built on an unparalleled 150-year heritage of optical innovation, Carl Zeiss Meditec AG (International Securities Identification Number DE000531370) is one of the world's leading eye care solutions providers.

Its product line includes systems for the diagnosis and treatment of the four main diseases of the eye: refraction, cataract, glaucoma and retinal disorders. The company has incorporated its technologically-superior optics into a stream of product innovations throughout the years, from slit lamps and fundus cameras to the Humphrey® Field Analyzer, recognised as the global standard for glaucoma detection and management, to its newest applications of lasers as embodied in its leading-edge MEL-80™ refractive laser and innovative STRATUSoct™ for glaucoma diagnosis.

Carl Zeiss Meditec AG is based in Jena, Germany, with key subsidiaries in the U.S. (Carl Zeiss Meditec, Inc.) and Japan (Carl Zeiss Meditec Ltd.). The rapidly aging global population and other trends are expected to generate long-term growth in the ophthalmic market. The company's activities are focused on applying innovative optical technologies to maintain and enhance vision today and in the future.

31 percent of the Carl Zeiss Meditec shares are in scattered holdings. The remaining 69 percent are held by Carl Zeiss, one of the world's leading international groups engaged in the optical and opto-electronics industry.

#### Contact:

### Investor relations

Jens Brajer/Director Investor Relations Göschwitzer Straße 51 -52 D-07745 Jena

Phone: +49 (0) 36 41 - 2 20 - 1 05 Fax: +49 (0) 36 41 - 2 20 -1 17

E-mail: investors@meditec.zeiss.com
Web: http://www.meditec.zeiss.de